MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, CRBP had $6,939K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$6,939K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-23,342 -34,640
Stock-based compensation expense
1,582 3,277
Depreciation expense
50 134
Net amortization of premiums and discounts on investments
50 624
Amortization of debt discount
0 0
Other
-47 289
Decrease in prepaid expenses and other current assets
-2,656 2,319
Decrease in other assets
0 0
Decrease in operating lease right-of-use assets
-267 -509
Decrease in other long-term liabilities
0 0
Decrease in accounts payable
-1,276 -509
Increase (decrease) in accrued expenses
4,923 2,224
Decrease in operating lease liabilities
-407 -783
Net cash used in operating activities
-15,550 -33,020
Purchases of investments
17,841 55,228
Proceeds from sales and maturities of investments
37,479 91,094
Net cash provided by (used in) investing activities
19,638 35,866
Proceeds from issuance of common stock, net
2,851 0
Repayment of notes payable
0 0
Repayment of long-term borrowings
0 0
Net cash provided by financing activities
2,851 0
Net increase in cash, cash equivalents, and restricted cash
6,939 2,846
Cash and cash equivalents at beginning of period
17,868 -
Cash and cash equivalents at end of period
27,653 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Corbus Pharmaceuticals Holdings, Inc. (CRBP)